Recent advances in liver-directed gene therapy: Implications for the treatment of dyslipidemia

Current Opinion in Lipidology

Volumn 11, Issue 2, 2000, Pages 179-186

  Oka, Kazuhiro ^a   Davis, Alan R ^a   Chan, Lawrence ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CIS ACTING ELEMENT; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; DYSLIPIDEMIA; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HEMOPHILIA B; LIPID BLOOD LEVEL; LIVER; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENE;

ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPIDEMIAS; LIPOSOMES; LIVER; MICE; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA;

EID: 0034006386     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200004000-00011     Document Type: Review

References (58)

1. 1 Chan L. Use of somatic gene transfer to study lipoprotein metabolism in experimental animals in vivo. Curr Opin Lipidol 1995; 6:335-340.
2. 2 Gerard RD, Chan L. Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Curr Opin Lipidol 1996; 7:105-111.
3. 3 Rader DJ, Tietge UJF. Gene therapy for dyslipidemia: clinical prospects. Curr Athero Rpt 1999; 1:58-69. A good review of experimental gene therapy in animal models.
4. 4 Belalcazar M, Chan L. Somatic gene therapy for dyslipidemias. J Lab Clin Med 1999; 134:194-214. A review covering broad topics for cardiovascular gene therapy.
5. 5 Smith AE. Gene therapy-where are we? Lancet 1999; 354 (Suppl. I):1-4. A comprehensive review of the problems and promise of somatic gene therapy as of the beginning of 1999.
6. 6 Verma IM, Somia N. Gene therapy-promises, problems and prospects. Nature 1997; 389:239-242.
7. 7 Anderson WF. Human gene therapy. Nature 1998; 392 (Suppl.):25-30. A review of some of the problems of somatic gene therapy in humans.
8. 8 VandenDriessche T, Vanslembrouck V, Goovaerts I, Zwinnen H, Vanderhaeghen M-L, Collen D, Chuah MKL. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci U S A 1999; 96:10379-10384.
9. 9 Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5:1052-1056. This paper defines insertion points in the AAV capsid for novel ligands that allow AAV to infect cell and tissues not ordinarily infected.
10. 10 Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72:4212-4223. This paper describes the surprising lack of cellular immunity against the transgene product upon infection of muscle fibers with recombinant AAV.
11. 11 Dong JY, Fan FD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996; 7:2101-2112.
12. 12 Ye X, Rivera VM, Zoltick P, Cerasoli Jr F, Schnell MA, Gao G, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283:8891. This is the first description of a regulated system for transgene expression in the AAV vector system.
13. 13 Tobiasch E, Rabreau M, Geletnedy K, Larue-Charlus S, Severin F, Becker N, Schlehofer JR. Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion. J Med Virol 1994; 44:215-222.
14. 14 Xiao W, Berta SC, Lu MM, Moscioni AD, Tazetaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998; 72:10222-10226. This paper is one of the first studies that indicates that the liver can be effectively transduced by an AAV vector. However, transduction efficiency is strongly dependent on the promoter used.
15. 15 Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH, Yang EY, et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998; 91:4600-4607.
16. 16 Koeberl DD, Bonham L, Halbert CL, Allen JM, Birkebak T, Miller AD. Persistent and therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors. Hum Gene Ther 1999; 10:2133-2140.
17. 17 Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94:5804-5809.
18. 18 Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A 1997; 94:1426-1431.
19. 19 Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther 1999; 6:1695-1704.
20. 20 Wang L, Takabe K, Bidlingmaier SM, III CR, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A 1999; 96:3906-3910.
21. 21 Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16:270-276.
22. 22 Girard C, Winocour E, Bern KI. Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence. Proc Natl Acad Sci U S A 1994; 91:10039-10043.
23. 23 Kotin RM, Siniscalco M, Samulski RF, Zhu XD, Hunter L, Laughlin CA, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1990; 87:221-226.
24. 24 Yang CC, Xiao X, Zhu X, Ansardi DC, Epstein ND, Frey MR, et al. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol 1997; 71:9231-9247.
25. 25 Shelling AN, Smith MG. Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene. Gene Ther 1994; 1:165-169.
26. 26 Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K, Natsoulis G. Adeno-associated virus rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997; 71:7951-7959.
27. 27 Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1999; 72:2224-2232. In this article the expression of AAV in the liver is systematically studied. It is noted that expression depends strongly on the choice of promoter and that from 0.1 to 2.0 copies of the recombinant AAV are integrated per cell.
28. 28 Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9:2745-2760.
29. 29 Inoue N, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol 1998; 72:7024-7031.
30. 30 Gao GP, Qu G, Faust LZ, Engdahl RK, Xiao W, Hughes JV, et al. High-titer adeno-associated viral vector from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9:2353-2362.
31. 31 Liu XL, Clark KR, Johnson PR. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther 1999; 6:293-299.
32. 32 Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud JM, et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997; 71:4626-4637.
33. 33 Wang Q, Greenburg G, Bunch D, Farson D, Finer MH. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Ther 1997; 4:393-400.
34. 34 Raper SE, Haskal ZJ, Ye X, Pugh C, Furth EE, Gao GP, Wilson JM. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. Hum Gene Ther 1998; 9:671-679.
35. 35 Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70:8934-8943.
36. 36 Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D, Mourot B, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998; 72:2022-2032.
37. 37 O'Neal WK, Zhou H, Morral N, Aguilar-Cordova E, Pestaner J, Langston C, et al. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1 -antitrypsin after systemic delivery. Hum Gene Ther 1998; 9:1587-1598.
38. 38 Pastore L, Morral N, Zhou H, Garcia R, Parks RJ, Kochanek S, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10:1773-1781. C3H/HeJ mouse strain develops antibodies to hAAT upon systemic expression mediated by a first-generation adenovirus. The authors report that the liver-specific albumin promoter fails to induce the humoral immune response to hAAT and hypothesize that transgene expression in antigen-presenting cells affect the development of host immune response.
39. 39 Lozier JN, Metzger ME, Donahue RE, Morgan RA. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 1999; 94:3968-3975. A toxicity analysis of adenoviral vectors in rhesus monkey.
40. 40 Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401:517-518.
41. 41 Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galacto-sidase. Proc Natl Acad Sci U S A 1996; 93:5731-5736.
42. 42 Kochanek S. High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 1999; 10:2451-2459. A comprehensive review of the helper-dependent adenoviral vectors.
43. 43 Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93:13565-13570.
44. 44 Chen H-H, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A 1997; 94:1645-1650.
45. 45 Floyd Jr SS, Clemens PR, Ontell MR, Kochanek S, Day CS, Yang J, et al. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 1998; 5:19-30.
46. 46 Chen HH, Mack LM, Choi SY, Ontell M, Kochanek S, Clemens PR. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 1999; 10:365-373.
47. 47 Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997; 71:3293-3298.
48. 48 Parks RJ, Bramson JL, Wan Y, Addison CL, Graham FL. Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J Virol 1999; 73:8027-8034. The authors analysed the limitations of DNA inserts in HD-Ad vectors and effects of stuffer DNA on transgene expression.
49. 49 Morsy MA, Gu MC, Motzel S, Zhao J, Lin J, Su Q, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998; 95:7866-7871.
50. 50 Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18:180-183.
51. 51 Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, Quinones J, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1 -antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9:2709-2716.
52. 52 Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A 1999; 96:12816-12821. This is the first report of HD-Ad vector administration into non-human primates. Sequential administration of first-generation adenovirus vectors of serotypes 2 and 5 was also investigated. This report demonstrates that long-term expression of transgenes at therapeutically effective levels can be accomplished by taking advantage of the reduced immunogenicity and toxicity of HD-Ad vectors and the possibility of the sequential delivery of vectors of different serotypes.
53. 53 Oka K, Kim I-H, Merched A, Pastore L, Beaudet AL, Chan L. Long-term expression of VLDL receptor by a helper-dependent adenoviral vector reduces atherosclerosis in a mouse model of familial hypercholesterolemia [Abstract]. Circulation Suppl 1999; 100:1-46.
54. 54 Harui A, Suzuki S, Kochanek S, Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999; 73:6141-6146.
55. 55 Parks RJ, Evelegh CM, Graham FL. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 1999; 6:1565-1573. This is the first report on the development of helper viruses based on alternative adenovirus serotypes. The authors demonstrate the feasibility of repeated HD-Ad vector administration using vectors of alternative serotypes.
56. 56 Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5:56-63.
57. 57 Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286:2244-2245.
58. 58 Hollon T. Researchers and regulators reflect on first gene therapy death. Nat Med 2000; 6:6.